Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD-1/PD-L1-refractory Merkel cell carcinoma-a case report

被引：1
|
作者：
Leven, Anna-Sophia [1 ]
Becker, Juergen C. [2 ,3 ]
Poettgen, Christoph [4 ]
Schadendorf, Dirk [1 ,5 ,6 ,7 ]
Ugurel, Selma [1 ,5 ,6 ,7 ]
Tasdogan, Alpaslan [1 ,5 ,6 ,7 ]
机构：
[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Dermatol Venereol & Allergol, Essen, Germany
[2] Univ Med, Translat Skin Canc Res, Essen, Germany
[3] German Canc Res Ctr, German Consortium Translat Canc Res DKTK, Heidelberg, Germany
[4] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Radiotherapy, Essen, Germany
[5] German Canc Consortium, Partner Site Essen, Essen, Germany
[6] Univ Duisburg Essen, Natl Ctr Tumor Dis NCT West, Campus Essen, Essen, Germany
[7] Univ Duisburg Essen, Res Ctr One Hlth, Res Alliance Ruhr, Essen, Germany
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2024年 / 63卷 / 02期
关键词：
OPEN-LABEL;
D O I：
10.1111/ijd.16986
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：e69 / e71
页数：3
相关论文
共 50 条
  • [41] PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
    Nghiem, Paul T.
    Bhatia, Shailender
    Lipson, Evan J.
    Kudchadkar, Ragini R.
    Miller, Natalie J.
    Annamalai, Lakshmanan
    Berry, Sneha
    Chartash, Elliot K.
    Daud, Adil
    Fling, Steven P.
    Friedlander, Philip A.
    Kluger, Harriet M.
    Kohrt, Holbrook E.
    Lundgren, Lisa
    Margolin, Kim
    Mitchell, Alan
    Olencki, Thomas
    Pardoll, Drew M.
    Reddy, Sunil A.
    Shantha, Erica M.
    Sharfman, William H.
    Sharon, Elad
    Shemanski, Lynn R.
    Shinohara, Michi M.
    Sunshine, Joel C.
    Taube, Janis M.
    Thompson, John A.
    Townson, Steven M.
    Yearley, Jennifer H.
    Topalian, Suzanne L.
    Cheever, Martin A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (26): : 2542 - 2552
  • [42] PD-1 checkpoint blockade is an emerging treatment for Merkel cell carcinoma
    Cassler, N. M.
    Brownell, I.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (01) : 18 - 18
  • [43] Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
    Glutsch, Valerie
    Graen, Franziska
    Weber, Judith
    Gesierich, Anja
    Goebeler, Matthias
    Schilling, Bastian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [44] Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma
    Albiges, Laurence
    Fay, Andre P.
    Xie, Wanling
    Krajewski, Katherine
    McDermott, David F.
    Heng, Daniel Y. C.
    Dariane, Charles
    DeVelasco, Guillermo
    Lester, Renee
    Escudier, Bernard
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (17) : 2580 - 2586
  • [45] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
    Xingming Zhang
    Xiaoxue Yin
    Haoran Zhang
    Guangxi Sun
    Yaojing Yang
    Junru Chen
    Xudong Zhu
    Peng Zhao
    Jinge Zhao
    Jiandong Liu
    Ni Chen
    Jia Wang
    Pengfei Shen
    Hao Zeng
    BMC Cancer, 19
  • [46] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
    Zhang, Xingming
    Yin, Xiaoxue
    Zhang, Haoran
    Sun, Guangxi
    Yang, Yaojing
    Chen, Junru
    Zhu, Xudong
    Zhao, Peng
    Zhao, Jinge
    Liu, Jiandong
    Chen, Ni
    Wang, Jia
    Shen, Pengfei
    Zeng, Hao
    BMC CANCER, 2019, 19 (1)
  • [47] Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
    Kammerer-Jacquet, Solene-Florence
    Deleuze, Antoine
    Saout, Judikael
    Mathieu, Romain
    Laguerre, Brigitte
    Verhoest, Gregory
    Dugay, Frederic
    Belaud-Rotureau, Marc-Antoine
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)
  • [48] Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
    Giraldo, Nicolas A.
    Nguyen, Peter
    Engle, Elizabeth L.
    Kaunitz, Genevieve J.
    Cottrell, Tricia R.
    Berry, Sneha
    Green, Benjamin
    Soni, Abha
    Cuda, Jonathan D.
    Stein, Julie E.
    Sunshine, Joel C.
    Succaria, Farah
    Xu, Haiying
    Ogurtsova, Aleksandra
    Danilova, Ludmila
    Church, Candice D.
    Miller, Natalie J.
    Fling, Steve
    Lundgren, Lisa
    Ramchurren, Nirasha
    Yearley, Jennifer H.
    Lipson, Evan J.
    Cheever, Mac
    Anders, Robert A.
    Nghiem, Paul T.
    Topalian, Suzanne L.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [49] THE ROLE OF COMBINATION IMMUNE CHECKPOINT INHIBITORS AS SALVAGE THERAPY FOR PD-1/PD-L1RESISTANT MERKEL CELL CARCINOMA
    Haykal, Tarek
    Beasley, Georgia
    Salama, April
    Hanks, Brent
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A862 - A862
  • [50] Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
    Spassova, Ivelina
    Ugurel, Selma
    Kubat, Linda
    Zimmer, Lisa
    Terheyden, Patrick
    Mohr, Annalena
    Andtback, Hannah Bjorn
    Villabona, Lisa
    Leiter, Ulrike
    Eigentler, Thomas
    Loquai, Carmen
    Hassel, Jessica C.
    Gambichler, Thilo
    Haferkamp, Sebastian
    Mohr, Peter
    Pfoehler, Claudia
    Heinzerling, Lucie
    Gutzmer, Ralf
    Utikal, Jochen S.
    Horny, Kai
    Schildhaus, Hans-Ulrich
    Habermann, Daniel
    Hoffmann, Daniel
    Schadendorf, Dirk
    Becker, Juergen Christian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
12345